{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:06:06Z","timestamp":1789373166463,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.msard.2026.107673","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:16:18Z","timestamp":1787210178000},"page":"107673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Alemtuzumab in Brazilian multiple sclerosis care: major gaps in mandatory monitoring over 24 months"],"prefix":"10.1016","volume":"114","author":[{"given":"Jo\u00e3o Lucas Silva","family":"Santana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1388-3684","authenticated-orcid":false,"given":"Matheus Rodrigues","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Pinho","family":"Cicivizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Abrah\u00e3o","family":"Allioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarso","family":"Adoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Luisa","family":"Ap\u00f3stolos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107673_bib0006","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade, Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade, 2021. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Esclerose M\u00faltipla. Minist\u00e9rio da Sa\u00fade, Bras\u00edlia. https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/pcdt\/e\/esclerose-multipla\/view (accessed 4 April 2026)."},{"issue":"11","key":"10.1016\/j.msard.2026.107673_bib0001","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2026.107673_bib0002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40263-024-01066-3","article-title":"Real-world retrospective analysis of alemtuzumab outcomes in relapsing-remitting multiple sclerosis: the LEMCAM study","volume":"38","author":"Costa-Frossard Fran\u00e7a","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2026.107673_bib0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.msard.2015.08.004","article-title":"Prevalence of multiple sclerosis in Brazil: a systematic review","volume":"4","author":"Pereira","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107673_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104581","article-title":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: a systematic review and meta-analysis","volume":"71","author":"Pipek","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107673_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104488","article-title":"Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in S\u00e3o Paulo, Brazil","volume":"70","author":"Silva","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107673_bib0009","article-title":"Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs","volume":"49","author":"Silva","year":"2025","journal-title":"Lancet Reg. Health Am."},{"key":"10.1016\/j.msard.2026.107673_bib0004","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107673_bib0003","first-page":"15","article-title":"Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis","author":"Yang","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600708X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600708X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:07:49Z","timestamp":1789369669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600708X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"alternative-id":["S221103482600708X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107673","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab in Brazilian multiple sclerosis care: major gaps in mandatory monitoring over 24 months","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107673"}}